

Amendments to the Claims:

This listing of claims will replace all prior versions and listings in the application:

LISTING OF CLAIMS:

Claim 1 (Currently amended): An inhalable powder composition comprising 0.001 to 3% of tiotropium, or a pharmaceutically acceptable salt thereof, in admixture with a physiologically acceptable excipient having an average particle size of 10 - 50 μm , a 10 % fine content of 0.5 to 6 μm and a specific surface of 0.1 to 2 m^2/g , wherein the physiologically acceptable excipient is lactose monohydrate characterized by a solution enthalpy of $\geq 50 \text{ J/g}$ selected from the group consisting of monosaccharides, disaccharides, oligo- and polysaccharides, polyalcohols and salts, and combinations thereof, and wherein the inhalable powder composition is delivered as a single dose from a powder reservoir composed of a material made from a synthetic plastic and wherein the excipient is not a mixture of excipients obtained by mixing together excipient fractions with different average particle sizes.

Claim 2 (Original): The composition according to claim 1 wherein the tiotropium is present as a salt in the form of the chloride, bromide, iodide, methanesulphonate or para-toluenesulphonate.

Claims 3-12 (Cancelled).